Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16508017
Järviluoma A, et al. (2006) Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 26, 2430-40 16508017
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S130-p - p21Cip1 (human)
Modsite: sGEQAEGsPGGPGDs SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): S130‑p, p21Cip1 (mouse): S125‑p, p21Cip1 (dog): S98‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Phosphoantibody to S129 only. NIH3T3 and U2OS stably infected with inducible K cyclin (from Kaposi's sarcoma herpesvirus).
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK6 (human)
Comments:  Cdk6/K Cyclin
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CDK6 (human) increase In presence of K cyclin
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  cell cycle regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CCND1 (human) Disrupts co-immunoprecipitation
CDK2 (human) Disrupts co-immunoprecipitation
Comments:  S130A but not wt p21Cip1 prevents S phase entry in presence of K cyclin

T145-p - p21Cip1 (human)
Modsite: QGRkRRQtsMTDFyH SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): T145‑p, p21Cip1 (mouse): T140‑p, p21Cip1 (dog): T113‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  Phosphoantibody to S129 only. NIH3T3 and U2OS stably infected with inducible K cyclin (from Kaposi's sarcoma herpesvirus).